Outputs (15)

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial (2022)
Journal Article
Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., …Zafar, A. (2023). Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet, 401(10373), 281-293. https://doi.org/10.1016/s0140-6736%2822%2902597-1

Background: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. W... Read More about Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries (2022)
Journal Article
Nguyen-Van-Tam, J. S., O'Leary, M., Martin, E. T., Heijnen, E., Callendret, B., Fleischhackl, R., …Weber, K. (2022). Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. European Respiratory Review, 31(166), Article 220105. https://doi.org/10.1183/16000617.0105-2022

Background Respiratory syncytial virus (RSV) significantly impacts the health of older and high-risk adults (those with comorbidities). We aimed to synthesise the evidence on RSV disease burden and RSV-related healthcare utilisation in both populatio... Read More about Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries.

The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom (2022)
Journal Article
Lim, W. W., Cowling, B. J., Nakafero, G., Feng, S., Nguyen-Van-Tam, J. S., & Bolt, H. (2022). The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom. Epidemiology and Infection, 150, Article E198. https://doi.org/10.1017/S0950268822001753

Annual seasonal influenza vaccination is recommended for individuals at high risk of developing post-infection complications in many locations. However, reduced vaccine immunogenicity and effectiveness have been observed among repeat vaccinees in som... Read More about The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom.

Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum) (2022)
Journal Article
Adams, L., Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Van-Tam, J. S., …Abhishek, A. (2022). Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum). British Journal of Dermatology, 188(2), 297-299. https://doi.org/10.1093/bjd/ljac061

Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return (2022)
Journal Article
Tan, L. J., Ahmed, S., Rothholz, M. C., Kassianos, G., & Nguyen-Van-Tam, J. S. (2022). Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return. Human Vaccines and Immunotherapeutics, 18(6), Article 2125754. https://doi.org/10.1080/21645515.2022.2125754

During the COVID-19 pandemic, immunization programs for other respiratory infections, notably influenza continued worldwide but attracted less public or political attention than COVID-19 vaccinations. Due to non-pharmaceutical intervention measures t... Read More about Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return.

Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis (2022)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., Williams, H. C., & Abhishek, A. (2023). Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Rheumatology, 62(4), 1445-1450. https://doi.org/10.1093/rheumatology/keac484

OBJECTIVES: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and autoimmune rheumatic disease (AIRD) flare. MATERIAL AND METHODS: Patients with AIRDs vaccinated against COVID-19 who consulted for dise... Read More about Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.

Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic (2022)
Journal Article
Fuller, A., Hancox, J., Vedhara, K., Card, T., Mallen, C., Van-Tam, J. S. N., & Abhishek, A. (2022). Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic. PLoS ONE, 17(9), Article e0267769. https://doi.org/10.1371/journal.pone.0267769

Objectives To explore barriers and facilitators to COVID-19, influenza, and pneumococcal vaccine uptake in immunosuppressed adults with immune-mediated inflammatory diseases (IMIDs). Methods Recruiting through national patient charities and a local h... Read More about Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic.

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial (2022)
Journal Article
Abhishek, A., Boyton, R. J., Peckham, N., McKnight, Á., Coates, L. C., Bluett, J., …Cook, J. A. (2022). Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine, 10(9), 840-850. https://doi.org/10.1016/S2213-2600%2822%2900186-2

Background: Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses against the... Read More about Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial (2022)
Journal Article
Shaw, R. H., Liu, X., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., …Okenyi, E. (2022). Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respiratory Medicine, 10(11), 1049-1060. https://doi.org/10.1016/S2213-2600%2822%2900163-1

Background: Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com... Read More about Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial (2022)
Journal Article
Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., …Hardy, A. (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, 22(8), 1131-1141. https://doi.org/10.1016/S1473-3099%2822%2900271-7

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of... Read More about Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) (2022)
Journal Article
Abhishek, A., Boyton, R. J., McKnight, Á., Coates, L. C., Bluett, J., Barber, V., …Cook, J. A. (2022). Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study). BMJ Open, 12(5), Article e062599. https://doi.org/10.1136/bmjopen-2022-062599

Introduction It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexa... Read More about Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).

Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves (2022)
Journal Article
Swann, O. V., Pollock, L., Holden, K. A., Munro, A. P., Bennett, A., Williams, T. C., …on behalf of ISARIC4C Investigators. (2022). Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. Pediatric Research, https://doi.org/10.1038/s41390-022-02052-5

Background: We hypothesised that theclinical characteristics of hospitalised children and young people(CYP) with SARS-CoV-2 in the UK second wave (W2) would differ from the firstwave (W1) due to the alpha variant (B.1.1.7), school reopening and relax... Read More about Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves.

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. (2022)
Journal Article
Liu, X., Munro, A. P. S., Feng, S., Janani, L., Aley, P. K., Babbage, G., …the COV-BOOST study group. (2022). Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Journal of Infection, 84(6), 795-813. https://doi.org/10.1016/j.jinf.2022.04.018

Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose. The analysis was con... Read More about Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial..

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults (2022)
Journal Article
Killingley, B., Mann, A. J., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., …Chiu, C. (2022). Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 28, 1031–1041. https://doi.org/10.1038/s41591-022-01780-9

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of cases and continues to circulate globally. To establish a novel SARS-CoV-2 human challenge model that enables controlled inve... Read More about Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study (2022)
Journal Article
Närhi, F., Ramani Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., …Docherty on behalf of the ISARIC4C investigators, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet. Digital Health, 4(4), e220-e234. https://doi.org/10.1016/S2589-7500%2822%2900018-8

Background: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial... Read More about Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.